

Stivarga® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below:					
<input type="checkbox"/> Advanced gastrointestinal stromal tumor (GIST)					
<input type="checkbox"/> Hepatocellular carcinoma (HCC)					
<input type="checkbox"/> Metastatic colorectal cancer (mCRC)					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
For advanced gastrointestinal stromal tumor (GIST), also answer the following:					
Can the tumor be surgically removed? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the patient's cancer metastatic? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the tumor no longer responsive to imatinib (Gleevec) and sunitinib (Sutent)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For hepatocellular carcinoma (HCC), also answer the following:					
Has the patient previously been treated with sorafenib (Nexavar)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For metastatic colorectal cancer (mCRC), also answer the following:					
Has the patient been previously treated with FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Has the patient been previously treated with anti-VEGF therapy (e.g., bevacizumab)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Does the patient have KRAS wild type metastatic colorectal cancer (mCRC)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
If "yes" to the above question, has the patient previously been treated with an anti-EGFR therapy (e.g., panitumumab or cetuximab)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Medication being provided by: (Please check applicable box below)					
<input type="checkbox"/> PropriumRx <input type="checkbox"/> Specialty Pharmacy (specify name): _____					
Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.					
Previous therapies will be verified through pharmacy paid claims or submitted chart notes.					
Prescriber Signature: _____				Date: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-800-711-4555.
 This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**
 Office use only: Stivarga_Optima_2018Jan-W